Christian LaPointe
About Christian LaPointe
Christian LaPointe, Ph.D., J.D., is General Counsel and Corporate Secretary of Quantum‑Si (QSI). He has served as GC since the Business Combination closing in June 2021 and previously as Legacy Quantum‑Si’s GC since November 2020; he is 54 years old and holds a B.S. in Biochemistry (University of New Hampshire), a Ph.D. in Biochemistry (Dartmouth College), and a J.D. (Suffolk University Law School) . Company performance during his tenure reflects improving TSR but persistent losses: cumulative TSR rose from 23.25 (2022) to 34.31 (2024), while net losses were $132.4M (2022), $96.0M (2023), and $101.0M (2024) .
Company Performance During LaPointe’s Tenure
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| TSR (Value of $100 investment) | 23.25 | 25.54 | 34.31 |
| Net Income ($USD Millions) | (132.4) | (96.0) | (101.0) |
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| ArcherDX, Inc. | General Counsel; later Deputy General Counsel | GC: Jan 2015–Aug 2019; Deputy GC: Aug 2019–Oct 2020 | Built legal function in genomics; supported corporate growth and transactions |
| Celsee, Inc. | General Counsel | Aug 2019–Jun 2020 | Legal oversight for single‑cell analysis solutions provider |
| Thrive Bioscience, Inc. | General Counsel | Aug 2014–Jul 2019 | Legal/compliance for cell culture instruments/software company |
| Enzymatics, Inc. | General Counsel | Mar 2013–Jan 2015 | Led legal matters for life sciences tools company |
| Axios Biosciences, LLC | General Counsel | Dec 2012–Dec 2014 | GC for oncology drug discovery company |
| Sherin & Lodgen LLP | Litigation Attorney | Apr 2012–Mar 2013 | Litigation experience at law firm |
External Roles
No public company directorships or external board roles are disclosed for LaPointe in QSI filings; he is listed as an executive officer (General Counsel & Corporate Secretary), not a director .
Fixed Compensation
- LaPointe is an executive officer but not a Named Executive Officer (NEO); therefore base salary, target bonus, and cash compensation details are not disclosed in the Summary Compensation Table .
Performance Compensation
- No RSU/PSU/option grant details or performance metric‑linked payouts are disclosed for LaPointe individually; NEO awards and option modifications described in 2024–2025 filings pertain to the CEO and CFO, not LaPointe .
Equity Ownership & Alignment
- Individual beneficial ownership is not tabulated for LaPointe; he is included within “All Current Directors and Executive Officers as a Group” in security ownership but without an individual line item .
- Insider Trading Policy covers rules on hedging, margin accounts, pledged securities, trading windows, and Rule 10b5‑1 plans; no pledging or hedging by LaPointe is disclosed .
- In Q3 2025, aside from Jonathan Rothberg’s estate‑planning 10b5‑1 sales plan, no other officers or directors adopted/modified/terminated trading arrangements under Item 408 (this implies LaPointe did not adopt a new plan that quarter) .
Employment Terms
- LaPointe is covered by the Quantum‑Si Executive Severance Plan.
| Term | Non‑CIC Termination (without cause) | Change‑in‑Control (CIC) Window Termination (without cause or for Good Reason) |
|---|---|---|
| Cash severance | 9 months of base salary | Lump sum of base salary + target bonus × 1.0 (for execs other than CEO) |
| Equity vesting | No acceleration disclosed outside CIC | All outstanding unvested equity becomes fully vested at termination date |
| COBRA | Company pays employer portion during severance period | Company pays employer portion for 12 months (execs other than CEO) |
| Conditions | Release of claims required to receive benefits | Release of claims required to receive benefits |
| CIC definition | >50% voting power change; qualifying merger/consolidation; sale of substantially all assets, subject to 409A and Class B voting carve‑out |
Board Governance
- QSI is a “controlled company” under Nasdaq rules; Jonathan Rothberg controls a majority of voting power via Class B shares (20 votes/share) .
- Compensation Committee is independent and engaged Aon Human Capital Solutions as independent consultant in 2024 .
Say‑On‑Pay & Shareholder Feedback
| Item | Votes For | Votes Against | Abstain | Broker Non‑Votes | Meeting Date |
|---|---|---|---|---|---|
| Advisory vote on NEO compensation | 438,851,268 | 1,446,598 | 179,587 | 37,711,052 | May 16, 2025 |
Performance & Track Record
- Governance execution: LaPointe regularly signs SEC filings and executed Board‑approved compensatory amendments (e.g., March 2024 8‑K on option modifications for CEO/CFO) and separation agreements (e.g., November 2025 CCO separation), indicating central responsibility for disclosure controls and corporate legal matters .
- Corporate Secretary duties: Led formal annual meeting procedures and forward‑looking statement disclosures during the 2025 AGM webcast .
Investment Implications
- Limited visibility into LaPointe’s personal pay mix and equity holdings reduces direct inference on his selling pressure or pay‑for‑performance alignment; however, he benefits from standardized executive severance economics (9 months cash; CIC 1.0× salary+target bonus and full acceleration), which moderately supports retention but could create CIC windfall optics if a transaction occurs .
- Absence of disclosed pledging/hedging and no new 10b5‑1 plan adoption during Q3 2025 lowers immediate alignment red flags; ongoing insider trading policy covers pledging/hedging governance .
- Controlled company status concentrates voting power with Rothberg, potentially diminishing minority shareholder influence on governance/compensation; legal function leadership by LaPointe is central to maintaining compliance rigor under this structure .